HomeCompareMKGAF vs RYLD

MKGAF vs RYLD: Dividend Comparison 2026

MKGAF yields 2.04% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MKGAF wins by $93.6K in total portfolio value· pulled ahead in Year 7
10 years
MKGAF
MKGAF
● Live price
2.04%
Share price
$122.45
Annual div
$2.50
5Y div CAGR
52.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.2K
Annual income
$57,634.11
Full MKGAF calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — MKGAF vs RYLD

📍 MKGAF pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKGAFRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKGAF + RYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKGAF pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKGAF
Annual income on $10K today (after 15% tax)
$173.61/yr
After 10yr DRIP, annual income (after tax)
$48,988.99/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, MKGAF beats the other by $46,789.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKGAF + RYLD for your $10,000?

MKGAF: 50%RYLD: 50%
100% RYLD50/50100% MKGAF
Portfolio after 10yr
$91.3K
Annual income
$30,110.73/yr
Blended yield
32.96%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKGAF buys
0
RYLD buys
0
No recent congressional trades found for MKGAF or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKGAFRYLD
Forward yield2.04%12.14%
Annual dividend / share$2.50$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.7%0%
Portfolio after 10y$138.2K$44.5K
Annual income after 10y$57,634.11$2,587.35
Total dividends collected$109.9K$18.8K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: MKGAF vs RYLD ($10,000, DRIP)

YearMKGAF PortfolioMKGAF Income/yrRYLD PortfolioRYLD Income/yrGap
1$11,012$311.88$11,914$1,213.65$902.00RYLD
2$12,273$490.13$14,099$1,351.30$1.8KRYLD
3$13,912$779.56$16,580$1,494.55$2.7KRYLD
4$16,146$1,261.05$19,384$1,642.61$3.2KRYLD
5$19,365$2,088.77$22,535$1,794.70$3.2KRYLD
6$24,296$3,575.17$26,063$1,950.00$1.8KRYLD
7← crossover$32,398$6,401.21$29,995$2,107.69+$2.4KMKGAF
8$46,847$12,181.47$34,361$2,266.99+$12.5KMKGAF
9$75,264$25,137.47$39,194$2,427.12+$36.1KMKGAF
10$138,167$57,634.11$44,525$2,587.35+$93.6KMKGAF

MKGAF vs RYLD: Complete Analysis 2026

MKGAFStock

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Full MKGAF Calculator →

RYLDETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this MKGAF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKGAF vs SCHDMKGAF vs JEPIMKGAF vs OMKGAF vs KOMKGAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.